Business Wire

MN-CAPILLARY-TECH

Share
Capillary Named a Leader in Loyalty Technology Solutions Report by Top Independent Research Firm

Capillary Technologies, a customer loyalty SaaS platform, has been named a Leader in “The Forrester WaveTM: Loyalty Technology Solutions, Q1 2023” report. Capillary’s Loyalty+ has earned 5/5 for 13 of the 28 criteria evaluated by Forrester.

The report, authored by Mary Pilecki and Cole Walsh, says that brands continue to invest in loyalty programs and loyalty technology solutions to help them engage and retain consumers — who are cutting back on spending and looking for more deals in response to higher prices. And according to Forrester’s Marketing Survey, 2023, “53% of B2C marketing decision-makers plan to increase their spend on loyalty technology in 2023, and economic uncertainty and scrutiny of marketing budgets has renewed marketers’ focus on the profitability of their loyalty strategies.”

Naming Capillary as a leader, the report states, “Capillary Technologies excels with robust tech capabilities and AI-powered nudges. Capillary Technologies offers a commerce solution, a customer data platform (CDP), and a loyalty platform, and expanded its loyalty reach by acquiring Persuade — a customer experience (CX) technology company — in 2021. Since then, Capillary has enhanced capabilities in its Loyalty+ offering for global clients in APAC, EMEA, and NA.”

In a Wave evaluation where 12 of the most significant vendors were considered, Capillary was evaluated to be one of only three leaders. “For us, this Forrester citation firmly establishes Capillary as a front-runner in the Loyalty Solutions space globally. For more than a decade now, we’ve helped hundreds of large enterprises realize the power of technology in delivering highly efficient loyalty programs to achieve the desired business outcomes. The evaluation in The Forrester Wave as a Leader is, in our opinion, a validation for the hard work the team has put in relentlessly over the years in helping brand marketers achieve extraordinary results and achieve customer loyalty as an outcome,” says Sameer Garde, CEO of Capillary Technologies.

The report further goes on to state, “Loyalty+ outpaces many in this competitive set because of robust functionality and a flexible data model. It excels in both loyalty program management and marketing, as well as in creating actionable insights from both customer and business data. And the platform’s 'nudges' feature leverages AI/ML to give marketers prescriptive advice on everything from program optimization to campaign management.”

About Capillary Technologies: Founded in 2012, Capillary Technologies has a presence across the United States, India, Middle East, and Asia, in particular, Southeast Asia. Capillary Technologies offers end-to-end loyalty programs, a comprehensive view of consumers and unified, cross-channel strategies that deliver a real-time omnichannel, personalized, and consistent experience for customers. Powering a diversified product suite of end-to-end loyalty programs, across 30+ countries, Capillary Technologies works with 250+ brands as of October 30, 2021, including Asics, PUMA, Shell, Tata, Fossil, Hoya, Pantaloons, GKB Opticals, Indian Terrain, Fossil, Vishal Megamart and many more from verticals such as apparel, footwear, supermarkets, conglomerates, manufacturing and electronics, pharmacy and wellness, fine dining and QSR, luxury and jewelry, entertainment, oil and gas, travel and hospitality. With a massive reach of 875 million+ consumers and processing 1.97 billion+ transactions in Fiscal 2021, Capillary Technologies’ promoter i.e., Capillary Technologies International Pte. Ltd. has the backing of Swanland Investment ltd. (an affiliate of Warburg Pincus), Sequoia Capital India Growth Fund II Ltd., Avataar Ventures Partners I, and Filter Capital Fund I Ltd. For more information, visit www.capillarytech.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005270/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye